346 related articles for article (PubMed ID: 28277834)
21. Antagonists of PD-1 and PD-L1 in Cancer Treatment.
Lipson EJ; Forde PM; Hammers HJ; Emens LA; Taube JM; Topalian SL
Semin Oncol; 2015 Aug; 42(4):587-600. PubMed ID: 26320063
[TBL] [Abstract][Full Text] [Related]
22. What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?
De Mello RA; Castelo-Branco L; Castelo-Branco P; Pozza DH; Vermeulen L; Palacio S; Salzberg M; Lockhart AC
Am Soc Clin Oncol Educ Book; 2018 May; 38():249-261. PubMed ID: 30231398
[TBL] [Abstract][Full Text] [Related]
23. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors.
Zhang L; Qiu M; Jin Y; Ji J; Li B; Wang X; Yan S; Xu R; Yang D
Int J Clin Exp Pathol; 2015; 8(9):11084-91. PubMed ID: 26617827
[TBL] [Abstract][Full Text] [Related]
24. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
25. Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer.
He J; Hu Y; Hu M; Li B
Sci Rep; 2015 Aug; 5():13110. PubMed ID: 26279307
[TBL] [Abstract][Full Text] [Related]
26. Changing strategies for target therapy in gastric cancer.
Lee SY; Oh SC
World J Gastroenterol; 2016 Jan; 22(3):1179-89. PubMed ID: 26811656
[TBL] [Abstract][Full Text] [Related]
27. Predictive biomarkers in gastric cancer.
Röcken C
J Cancer Res Clin Oncol; 2023 Jan; 149(1):467-481. PubMed ID: 36260159
[TBL] [Abstract][Full Text] [Related]
28. Targeted Therapies in Advanced Gastric Cancer.
Patel TH; Cecchini M
Curr Treat Options Oncol; 2020 Jul; 21(9):70. PubMed ID: 32725377
[TBL] [Abstract][Full Text] [Related]
29. Targeted therapies in gastric cancer and future perspectives.
Yazici O; Sendur MA; Ozdemir N; Aksoy S
World J Gastroenterol; 2016 Jan; 22(2):471-89. PubMed ID: 26811601
[TBL] [Abstract][Full Text] [Related]
30. Current and Future Therapies for Advanced Gastric Cancer.
Davidson M; Okines AF; Starling N
Clin Colorectal Cancer; 2015 Dec; 14(4):239-50. PubMed ID: 26524924
[TBL] [Abstract][Full Text] [Related]
31. PD-1 and PD-L1 blockade in gastrointestinal malignancies.
Lote H; Cafferkey C; Chau I
Cancer Treat Rev; 2015 Dec; 41(10):893-903. PubMed ID: 26412280
[TBL] [Abstract][Full Text] [Related]
32. Companion diagnostics for the targeted therapy of gastric cancer.
Yoo C; Park YS
World J Gastroenterol; 2015 Oct; 21(39):10948-55. PubMed ID: 26494953
[TBL] [Abstract][Full Text] [Related]
33. Gastric Carcinoma: Recent Trends in Diagnostic Biomarkers and Molecular Targeted Therapies.
Majeed W; Iftikhar A; Khaliq T; Aslam B; Muzaffar H; Atta K; Mahmood A; Waris S
Asian Pac J Cancer Prev; 2016; 17(7):3053-60. PubMed ID: 27509928
[TBL] [Abstract][Full Text] [Related]
34. Programmed Death-1 Ligand-1 (PDL1) Expression Is Associated with the Prognosis of Patients with Stage II/III Gastric Cancer.
Tamura T; Ohira M; Tanaka H; Muguruma K; Toyokawa T; Kubo N; Sakurai K; Amano R; Kimura K; Shibutani M; Maeda K; Hirakawa K
Anticancer Res; 2015 Oct; 35(10):5369-76. PubMed ID: 26408698
[TBL] [Abstract][Full Text] [Related]
35. Biomarkers of drugs targeting HER-family signalling in cancer.
Montemurro F; Scaltriti M
J Pathol; 2014 Jan; 232(2):219-29. PubMed ID: 24105684
[TBL] [Abstract][Full Text] [Related]
36. Current advances in targeted therapies for metastatic gastric cancer: improving patient care.
Aguiar PN; Muniz TP; Miranda RR; Tadokoro H; Forones NM; Monteiro ID; Castelo-Branco P; Janjigian YY; De Mello RA
Future Oncol; 2016 Mar; 12(6):839-54. PubMed ID: 26838766
[TBL] [Abstract][Full Text] [Related]
37. Contactin 1: A potential therapeutic target and biomarker in gastric cancer.
Chen DH; Yu JW; Jiang BJ
World J Gastroenterol; 2015 Sep; 21(33):9707-16. PubMed ID: 26361417
[TBL] [Abstract][Full Text] [Related]
38. HER2 testing in gastric cancer: An update.
Abrahao-Machado LF; Scapulatempo-Neto C
World J Gastroenterol; 2016 May; 22(19):4619-25. PubMed ID: 27217694
[TBL] [Abstract][Full Text] [Related]
39. The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.
Muenst S; Soysal SD; Tzankov A; Hoeller S
Expert Opin Ther Targets; 2015 Feb; 19(2):201-11. PubMed ID: 25491730
[TBL] [Abstract][Full Text] [Related]
40. Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature.
Matboli M; El-Nakeep S; Hossam N; Habieb A; Azazy AE; Ebrahim AE; Nagy Z; Abdel-Rahman O
World J Gastroenterol; 2016 Jul; 22(26):5896-908. PubMed ID: 27468184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]